Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer.

Andreas SperlichAlexander BalmertDietrich DollSabine BauerFabian FrankeGisela KellerDirk WilhelmAnna MurMichael RespondekHelmut FriessUlrich NitscheKlaus-Peter Janssen

Published in: BMC cancer (2018)

Integrative biomarker analysis allows stratification of stage III colon cancer patients for the risk of metastatic disease recurrence and may indicate response to 5-FU. Thus, biomarker analysis might facilitate the use of adjuvant therapy for high risk patients.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
small cell lung cancer
peritoneal dialysis
patient reported outcomes
dna methylation